Loading organizations...
Shanghai Qingrong Chuangzhi Group operates as a biotechnology company, engaged in the development of scientific solutions within the life sciences. Its technical approach leverages advanced biological principles to address various industry needs. The company is an affiliate of the West Coast New Area Fusion Holding Group, which provides a broader strategic and operational framework for its activities within the competitive biotech landscape.
The company's founding details, including specific founders and their initial insights that propelled its establishment, are not publicly disclosed. Its formation likely arises from strategic decisions and corporate initiatives within the West Coast New Area Fusion Holding Group, indicating an origin rooted in organizational planning rather than a singular entrepreneurial beginning driven by individual pedigree.
Shanghai Qingrong Chuangzhi Group serves clients across the healthcare and life sciences sectors, providing specialized biotechnological applications. Its long-term vision is to contribute meaningfully to advancements in biotechnology through innovative solutions. The company aims to address key biological challenges and foster ongoing scientific progress, positioning itself as a relevant entity in the future of life sciences development.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Dec 27, 2023 | Weihansi Shengwu | $14.0M Series B | Shanghai Qingrong Chuangzhi Group | — |